Seneschal Advisors’s Lyell Immunopharma LYEL Stock Holding History

Seneschal Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-126	Closed	-$2.53K	–	614
2026 Q1	$2.53K	Buy	+126	New	+$2.94K	﹤0.01%	175

Other funds holding LYEL

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Seneschal Advisors's LYEL Position: Q2 2026 in Review

Seneschal Advisors sold out of Lyell Immunopharma (LYEL) in Q2 2026, closing a stake of 126 shares — an estimated $2.53K sold.

Seneschal Advisors first reported a position in LYEL in Q1 2026 and held it in 1 quarter. The position peaked at $2.53K in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

Seneschal Advisors reported no remaining Lyell Immunopharma position as of Q2 2026 after selling out during the quarter.
Seneschal Advisors sold 126 Lyell Immunopharma shares in Q2 2026, an estimated $2.53K.
Seneschal Advisors first reported a position in Lyell Immunopharma in Q1 2026 and held it in 1 quarter.
Seneschal Advisors's Lyell Immunopharma position peaked at $2.53K in Q1 2026.
87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Seneschal Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.